GENE ONLINE|News &
Opinion
Blog

2025-04-25| Trending

World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access

by Steven Chung
Share To
"Today, we face the great unraveling — an anti-science regression back toward a world we thought we had left behind, where vaccine-preventable diseases remain and return, fueled by misinformation, mistrust, and denial." Image source: World Vaccine Congress

The World Vaccine Congress Washington 2025 was held from April 21 to 24 in Washington, D.C.. It was drawing to a successful close after bringing together leading experts in vaccine research and manufacturing, along with stakeholders from across the biotech industry and innovative startups. The conference offered a comprehensive academic and business platform. It features themes ranging from clinical trials, bioprocessing, vaccine safety and supply chain logistics, to antimicrobial resistance, global health, and biodefense.

Global Biotech Leaders Unite to Drive Vaccine Innovation

A key focus of this year’s forum was on strategies to meet the ambitious “100 Days Mission” — rapidly developing and reviewing vaccine prototypes within a 100-day window. Discussions explored next-generation mRNA platforms for indications such as respiratory syncytial virus (RSV), influenza, and HIV. Innovative delivery technologies. This includes virus-like particle (VLP) vaccines and microneedle patches, also garnered significant attention, with the aim of reducing cold-chain dependence and improving vaccine accessibility.

Pfizer highlighted its supply chain strategies and process optimization initiatives under the “100 Days Mission” theme. It emphasizes its capacity for rapid scale-up and global distribution. GlaxoSmithKline (GSK) shared the latest developments in its protein subunit vaccines and novel adjuvants, underscoring a science-driven innovation model. AstraZeneca presented plans for its multivalent tumor immunotherapy vaccines currently in clinical development.

Confronting Challenges: Rebuilding Trust and Strengthening Collaboration

On the evening of April 22, a spokesperson from the U.S. Department of Health and Human Services (HHS) stated that no final decision had been made. It regards the removal of COVID-19 vaccines from the recommended immunization schedule for children.

Earlier that morning, Dr. Gregory A. Poland, Chair of the World Vaccine Congress and Director of the Vaccine Research Group at Mayo Clinic, addressed the assembly with a warning:

“Today, we face the great unraveling — an anti-science regression back toward a world we thought we had left behind, where vaccine-preventable diseases remain and return, fueled by misinformation, mistrust, and denial.”

Global Collaboration and Access Lead the Fight Against Future Pandemics

The congress also featured keynote addresses from academic and nonprofit leaders, including those from the International AIDS Vaccine Initiative (IAVI). It emphasizes the importance of long-term investment and equitable global access to vaccines. Attendees widely agreed that accelerating clinical review timelines and harmonizing regulatory standards are essential to ensuring that scientific advances in vaccines reach populations around the world in a timely manner.

Through events like the World Vaccine Congress, the global health community is reinforcing cross-sector collaboration and international regulatory alignment. It was laying a solid foundation for addressing future emerging infectious disease threats.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns
2025-04-15
Controversy Surrounds Jay Bhattacharya’s Nomination as NIH Director
2025-03-05
LATEST
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
NIH Restores Research Funding to Previously Defunded Scientists Amid Policy Shifts
2025-05-20
Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20
Trump Science Adviser Michael Kratsios Calls for Renewed Focus on Reproducible Research Practices to Address Scientific Stagnation
2025-05-20
House Republicans Propose $700 Billion Medicaid Savings with Work Requirements
2025-05-20
EVENT
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top